this almost never happens. a RS would most likely signal weak or negative results. no one wants an RS. more likely, zlcs will run up above 1.00 we approach the october deadline, and zlcs will leak some positive data. if zlcs says nothing, then we know the data did not meet the endpoints. we will see an RS, dilution, and most likely an end to zlcs.
but i doubt this will happen. an RS would eat into the profit margins of investors. this always happens with small biotech stocks. it is just psychological. easier for a stock to go from .78 to 7 than 5 to 45
good for you. dont be intimidated by the longs we see this in all the other yahoo MB. every biotech has the same kind of investors. greedy, blind, and unable to accept criticism.
doing the RS so early, when zlcs would have easily remained over 1 for 7 more days, does not bode well. it isnt worth the risk. if z160 trial is anything but 100% positive - and the last trial did NOT meet all the endpoints, hence the downward trend - ZALICUS is DONE for good. is that acceptable risk? especially when management has been so tight-lipped, and virtually all the insight we get are from bag holders?
dont get married to the stock.
i had 5,000 into zlcs and couldnt stomach a potential loss. i made about 20% gain which is OKAY but better than a 50% loss.
i know i know, condemn me as a basher. but the RS done so early, when zlcs would have remained above 1 for another 7 days easily, is suspicious. big investors arent going to bother with zlcs until the trial data is released. anyone who says they would buy before dont know what they are talking about. unless zlcs slips some inside information soon we wont see any major investment unless the endpoints are met.
good luck to the LONGS. seriously i would hate to see this stock go down.
yea, assuming the data is positive, and that doesnt mean z160 will be a drug. most biotech drugs never get developed. yet we here this story all the time. sometimes you luck out with acad, but you will get burned 99% of the time. i took my profits and will continue to take profits. i learned my lesson, dont get greedy!
uh, what makes u say this? did titan appeal the fda ruling? no. has the fda ever voluntarily back downed on a ruling without an appeal? no, dont think. why did titan and braeburn re-negotiate their partnership, with titan forfeiting more front-end royalties in exchange for braeburn assuming more of the burden on future research and trials? because they are preparing for the fda to say more human trials.
and the drug's max market potential is MAYBE 300 million MAYBE, which gives ttnp a max pps of 2.00-2.50. and for many year, that's barely double.
worth the risk?
when has any biotech released nws over the weekend? it is always right before the market opens, like 4am on a monday.
i think this is a slight run up in anticipation for the meeting, but the big guys will sell and take some profits. i think we will see this continue. pps will probably be close to 2 right before the meeting.
not a technical investment. rnn is selling them NEW shares. investors are not buying outstanding shares, this dilutes the share price and makes individual shares less valuable.
this is completely false. an RS 9 out of 10 times ALWAYS leads to a dive in pps. i have yet to see a case in small cap biotech where an RS led to increased institutional investment. nbs is only one example where the pps maintained, but it didnt shoot up in a huge way.
UNLESS there are institutional investors lined up and only require an RS, a unilateral RS will always crush shareholders. we see this stupid posts in all biotech boards and the noobs get sucked into it. dont buy it. i hope oncs does not do an RS now.
i have to agree. i have a feeling ttnp isnt going to release the minutes until the very last day (19th) so i have until thn to sell. i would have taken .90 gladly and eating the loss. this stock isnt worth the headache, the only people in it are pumpers or people with super low averages like titan humper.
sunil is acting in his own self interest. his1 million+ salary is UNREAL considering the financial status of its titan and drug prospects. even ACAD's original ceo took less than 500k annual and their financials were better and drug pipeline more promising prior to their break out.
sunil is just a snake.
the meeting has no chance of approval since it wasn't an appeal. the only goodness will be fda saying ttnp does not need more human trials. anything less than that and the pps will tank overnight. im amused seeing all these threads get thumbs down, but any threads that praise ttnp without acknowledging the obvious risk get green all around.
ignore the down votes. in the end, it's the day traders who make consistent earnings while most longs in biotech lose their money. this is a sad reality. i am LONG zlcs, hut not an idiot. people are happy because of the SA article, which - if any of you read it - is basically a rehash of all the positives we have heard in the past, combined with the concern for the RS.
we will see a pull back towards .74, vote me down all you want. i will buy then.
this is a bit dishonest. ino ran on merk rumor buyout, since then it surges on rumor or small deals with big pharma. it was 3 dollars a few weeks ago and lost 1/3 of its worth overnight. the longs made money but people who bought during the gains lost.
so by ur logic, comparing ttnp means new investors will lose money because it will fall back to 1-1.50 when it hits 3 for whatever dumb reason. ttnp will probably hit 2 in anticipation of FDA meeting in november.
300% gain starting from where? INO was 3 not so long ago, so that's a 30% loss. not everyone has an average of .50 cents.
in the end swing traders will reap most of the profits. longs r motivated by religion and greed, not real actual profit. you want to make millions rather than thousands. i thought i was wrong about ino with roche, but now i see it was really nothing for roche and everything for ino. ino has its work cut out, at least long-term, so there is really no reason to hold onto INO indefinitely. if you are in at .50 might as well sell and take that 300% gain, and buy back in at 1.50 or 1.00, which will happen eventually.
ino is filled with more pumpers than bashers, and the bashers have been more right than the pumpers. i sold at 2.50. almost got married to ino. almost did the same with zlcs, and came out ahead.
you guys may luck out and ino will hit 20, but the chances r slim.
i doubt ttnp will ever get that low even if fda demands more trials. ttnp is so far into this drug, and since it already received majority support from fda committees, clearly the science is there. i think the problems are more technical and the fda is applying double standards, but ttnp has themselves to blame for not doing enough. imo i think the management has no incentive to help the shareholders since nothing happens to them no matter how the stock performs. but many dont have the stomach for the long hall, and even if ttnp goes up 50% that is barely a profit for most of us.
Key Executive Compensation 972,476 2,236,996 430,455 979,035 1,239,590
Sunil Bhonsle/President and Chief Financial Officer 468,355 1,019,876 277,473 568,020 703,140
Marc Rubin/Executive Chairman of the Board 504,121 1,217,120 152,982 411,015 536,450
ok please answer honestly. i am quite ignorant on the orphan drug status situation. does this mean the FDA has inside knowledge of the drug, or do they only have access to the same info we do? i think zlcs will pull back a bit next week as traders take their profits, then continue well past a dollar. but that's just me. acad did the same. anyways thoughts??
i think i may sell most of my shares rather than risk losing my investment. im looking at ttnp and oncs, as well as RN as replacements. i cant stomach the thought of losing 50% of my investment. if zlcs gave us a little tease of the trial data that would be nice. they must know something. this RS wasnt done for nothing.